Eli Lilly and Co
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the […]
Read More
Eli Lilly’s price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk
Sopa Images | Lightrocket | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading day: 1. No-tech November Last week’s recovery rally allowed the Dow Jones Industrial Average and S&P 500 to both finish their seventh […]
Read More
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Drug pricing has emerged as a key topic to watch for pharmaceutical companies and investors in 2025. As President Donald Trump pushes for lower medicine prices for Americans, the sector is facing additional pricing pressure from a Biden-era law called the Inflation Reduction Act. The IRA, voted into law in 2022, allows the Centers for […]
Read More
CNBC Daily Open: A turnaround in sentiment for U.S. markets may be in the cards
Traders work on the floor of the New York Stock Exchange (NYSE) on Nov. 21, 2025 in New York City. Spencer Platt | Getty Images Last week on Wall Street, two forces dragged stocks lower: a set of high-stakes numbers from Nvidia and the U.S. jobs report that landed with more heat than expected. But […]
Read More
CNBC Daily Open: Some hope after last week’s U.S. market rout
Traders work on the floor of the New York Stock Exchange (NYSE) on Nov. 21, 2025 in New York City. Spencer Platt | Getty Images Last week on Wall Street, two forces dragged stocks lower: a set of high-stakes numbers from Nvidia and the U.S. jobs report that landed with more heat than expected. But […]
Read More
The Street’s bad call on Palo Alto – plus, two portfolio stocks reach new highs
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The S & P 500 bounced back Friday, recovering from the prior session’s sharp losses. The broad-based index, which was still tracking for a nearly […]
Read More
Eli Lilly hits $1 trillion market value, a first for a health-care company
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly reached a $1 trillion market capitalization on Friday, the first health-care company in the world to join the exclusive club dominated by tech firms. Eli Lilly briefly hit […]
Read More
Obesity-drugmaker Novo Nordisk helps drive Denmark’s fastest growth in years
Denmark’s economic growth accelerated in the third quarter, boosted by strong pharmaceutical exports, a key industry for the small Nordic country home to weight loss drugmaker Novo Nordisk. Denmark’s seasonally adjusted gross domestic product (GDP) grew by 2.3% in the third quarter, the largest quarter-on-quarter expansion since the fourth quarter of 2021, a preliminary reading […]
Read More
Meta’s big antitrust win, Salesforce’s deal closure, and iPhone’s popularity in China
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks continued their recent declines Tuesday as megacap tech lagged on worries about valuations within the artificial intelligence trade. The S & P 500 was […]
Read More
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to […]
Read More